UNITEDHEALTH GROUP: BARCLAYS INCREASES TARGET PRICE TO $373, UP FROM $327
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy UNH?
Source: moomoo
Barclays Raises Price Target: Barclays has increased its price target for UnitedHealth Group from $327 to $373.
Market Implications: This adjustment reflects Barclays' positive outlook on UnitedHealth's performance and potential growth in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 366.770
Low
330.00
Averages
397.82
High
444.00
Current: 366.770
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, and social well-being. Optum Health delivers primary, specialty and surgical care and helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UnitedHealth Group Exceeds Quarterly Expectations
- Cost Control Success: UnitedHealth Group's medical benefit ratio for the quarter was 83.9%, lower than the expected 85.5%, enabling the company to achieve adjusted earnings per share of $7.23, significantly exceeding the forecast of $6.57, which boosts investor confidence in its cost management effectiveness.
- Strong Revenue Growth: The company reported total revenue of $111.7 billion for the quarter, surpassing Wall Street's estimate of $109.6 billion, indicating its competitive position in the market and sustained customer demand, potentially laying the groundwork for future business expansion.
- Regulatory Risks Unresolved: Despite the positive performance, ongoing investigations into UnitedHealth's billing practices, particularly regarding aggressive strategies in its Medicare Advantage operations, may lead to stricter regulations that could impact its operational model and revenue.
- Cautious Investor Sentiment: Following a 35% drop in stock price last year, investors remain cautious despite recent performance improvements, needing to observe whether the company can sustain its results to prove the stock's safety and investment value.
See More
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
UnitedHealth Group Reports Strong Quarterly Results Amid Ongoing Risks
- Strong Performance: UnitedHealth Group reported adjusted earnings per share of $7.23 for the quarter, exceeding analyst expectations of $6.57, showcasing the company's success in cost reduction, although the medical benefit ratio stood at 83.9%, down from 84.8% a year ago.
- Revenue Growth: The company achieved revenue of $111.7 billion this quarter, surpassing Wall Street's estimate of $109.6 billion, indicating an improvement in market performance that may attract more investor interest in the health insurance sector.
- Potential Risks: Despite the encouraging results, the company is under investigation regarding its billing practices, particularly Senator Chuck Grassley's concerns about its Medicare Advantage operations, which could lead to future regulatory restrictions impacting financial performance.
- Cautious Investment: Given the backdrop of a 35% decline in stock price over the past year, investors should remain cautious, waiting for the company to further prove the safety and long-term growth potential of its stock.
See More
UnitedHealth Group Reports Strong Q1 Results with 7% Share Surge
- Strong Earnings Beat: UnitedHealth Group reported Q1 revenue of $111.7 billion, reflecting a 2% year-over-year growth that exceeded estimates by $2.06 billion, with adjusted EPS of $7.23 surpassing expectations by $0.63, indicating robust recovery potential in the healthcare sector.
- Margin Expansion: The company improved its Medical Care Ratio to 83.9%, better than the expected 85.5%, representing a 90-basis-point increase from the prior year, showcasing management's confidence in future profitability and prompting an upward revision of the 2026 EPS outlook to over $18.25.
- AI Investment Initiative: UnitedHealth has committed $1.5 billion for AI investments in 2026 aimed at streamlining administrative workflows and claims processing, which is expected to enhance operational efficiency and strengthen competitive positioning through technological innovation.
- Stock Buyback Plan: The company plans to repurchase at least $2 billion of its common stock by the end of Q2 2026, further enhancing shareholder value, while also completing the sale of its Optum UK business, generating $400 million in net proceeds to support future growth strategies.
See More
UnitedHealth Group Shares Surge 30% in 30 Days
- Financial Recovery: UnitedHealth's Q1 revenue rose 2% year-over-year to $111.7 billion, with adjusted earnings per share at $7.23, slightly above last year's $7.20 but significantly up from $2.11 in Q4 2025, indicating recovery post-restructuring.
- Improved Medical Cost Management: The medical care ratio decreased to 83.9% in Q1 from 84.8% a year ago, attributed to strong cost management despite elevated utilization trends, which is crucial for enhancing profitability that was previously under pressure.
- Upgraded Full-Year Guidance: Management raised its 2026 adjusted earnings outlook to over $18.25 per share from $17.75, with the current stock price reflecting about 19 times the low end of this guidance, suggesting market confidence in future growth.
- Membership Attrition Concerns: Despite positive overall performance, UnitedHealth's membership dropped to 49.1 million in Q1 from 49.8 million at the end of 2025, with a notable decline of 965,000 seniors in Medicare Advantage, posing potential long-term growth challenges.
See More
UnitedHealth Group Exceeds Quarterly Expectations
- Cost Control Success: UnitedHealth Group's medical benefit ratio for the quarter was 83.9%, lower than the expected 85.5%, enabling the company to achieve adjusted earnings per share of $7.23, significantly exceeding the forecast of $6.57, which boosts investor confidence in its cost management effectiveness.
- Strong Revenue Growth: The company reported total revenue of $111.7 billion for the quarter, surpassing Wall Street's estimate of $109.6 billion, indicating its competitive position in the market and sustained customer demand, potentially laying the groundwork for future business expansion.
- Regulatory Risks Unresolved: Despite the positive performance, ongoing investigations into UnitedHealth's billing practices, particularly regarding aggressive strategies in its Medicare Advantage operations, may lead to stricter regulations that could impact its operational model and revenue.
- Cautious Investor Sentiment: Following a 35% drop in stock price last year, investors remain cautious despite recent performance improvements, needing to observe whether the company can sustain its results to prove the stock's safety and investment value.
See More
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
UnitedHealth Group Reports Strong Quarterly Results Amid Ongoing Risks
- Strong Performance: UnitedHealth Group reported adjusted earnings per share of $7.23 for the quarter, exceeding analyst expectations of $6.57, showcasing the company's success in cost reduction, although the medical benefit ratio stood at 83.9%, down from 84.8% a year ago.
- Revenue Growth: The company achieved revenue of $111.7 billion this quarter, surpassing Wall Street's estimate of $109.6 billion, indicating an improvement in market performance that may attract more investor interest in the health insurance sector.
- Potential Risks: Despite the encouraging results, the company is under investigation regarding its billing practices, particularly Senator Chuck Grassley's concerns about its Medicare Advantage operations, which could lead to future regulatory restrictions impacting financial performance.
- Cautious Investment: Given the backdrop of a 35% decline in stock price over the past year, investors should remain cautious, waiting for the company to further prove the safety and long-term growth potential of its stock.
See More
UnitedHealth Group Reports Strong Q1 Results with 7% Share Surge
- Strong Earnings Beat: UnitedHealth Group reported Q1 revenue of $111.7 billion, reflecting a 2% year-over-year growth that exceeded estimates by $2.06 billion, with adjusted EPS of $7.23 surpassing expectations by $0.63, indicating robust recovery potential in the healthcare sector.
- Margin Expansion: The company improved its Medical Care Ratio to 83.9%, better than the expected 85.5%, representing a 90-basis-point increase from the prior year, showcasing management's confidence in future profitability and prompting an upward revision of the 2026 EPS outlook to over $18.25.
- AI Investment Initiative: UnitedHealth has committed $1.5 billion for AI investments in 2026 aimed at streamlining administrative workflows and claims processing, which is expected to enhance operational efficiency and strengthen competitive positioning through technological innovation.
- Stock Buyback Plan: The company plans to repurchase at least $2 billion of its common stock by the end of Q2 2026, further enhancing shareholder value, while also completing the sale of its Optum UK business, generating $400 million in net proceeds to support future growth strategies.
See More
UnitedHealth Group Shares Surge 30% in 30 Days
- Financial Recovery: UnitedHealth's Q1 revenue rose 2% year-over-year to $111.7 billion, with adjusted earnings per share at $7.23, slightly above last year's $7.20 but significantly up from $2.11 in Q4 2025, indicating recovery post-restructuring.
- Improved Medical Cost Management: The medical care ratio decreased to 83.9% in Q1 from 84.8% a year ago, attributed to strong cost management despite elevated utilization trends, which is crucial for enhancing profitability that was previously under pressure.
- Upgraded Full-Year Guidance: Management raised its 2026 adjusted earnings outlook to over $18.25 per share from $17.75, with the current stock price reflecting about 19 times the low end of this guidance, suggesting market confidence in future growth.
- Membership Attrition Concerns: Despite positive overall performance, UnitedHealth's membership dropped to 49.1 million in Q1 from 49.8 million at the end of 2025, with a notable decline of 965,000 seniors in Medicare Advantage, posing potential long-term growth challenges.
See More
